Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 4/20 | 0.58 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | CHKA | P35790 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KHK | P50053 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001193 | 0.85 | SMO (0.65) | SMOSLC34A1RECQLDRD2DRD4 | |
| SCHEMBL5209503 | 0.77 | ALDH1A1 (0.43) | SMOLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1999559 | 0.75 | SMO (0.65) | SMOSLC34A1RECQLDRD2DRD4 | |
| SCHEMBL1997979 | 0.71 | SMO (0.60) | SMODRD2DRD4DRD3CHKA | |
| SCHEMBL1999864 | 0.71 | CYP2C9 (0.50) | LMNAMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL31500050 | 0.70 | SMN1; SMN2 (0.56) | LMNAMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL5224110 | 0.70 | KMT2A (0.50) | LMNAMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL5737789 | 0.70 | SMO (0.44) | SMODRD2DRD4DRD3LMNA | |
| SCHEMBL9961631 | 0.70 | SMO (0.59) | SMOSLC34A1RECQLDRD2DRD4 | |
| SCHEMBL11247967 | 0.70 | CYP2C9 (0.56) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611094-B1 | PYRAZOLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2007-06-20 | — | — | EP | disclosed |
| US-20060276650-A1 | Pyrazole compounds | MERCK PATENT GMBH (DE) | 2006-12-07 | — | — | US | disclosed |
| EP-1611094-A1 | PYRAZOLE COMPOUNDS | MERCK PATENT GmbH (DE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089888-A1 | PYRAZOLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276650-A1 | Pyrazole compounds | HTR1D, HTR1A, HTR3A | SMO 3168/4885SLC34A1 554/4885RECQL 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.